Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 15/20 | 0.56 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.42 |
| ▸ | TUBB | P07437 | 1/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.42 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.42 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.42 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.42 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.42 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.42 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.42 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.42 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.42 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.42 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.42 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15711419 | 0.76 | MAP2 (0.64) | MAP2SIRT1KDM4EALDH1A1 | |
| SCHEMBL14068344 | 0.76 | LMNA (0.44) | MAP2SIRT1KDM4EALDH1A1HPGD | |
| SCHEMBL12228524 | 0.75 | MAP2 (0.41) | MAP2SIRT1KDM4E | |
| SCHEMBL2028102 | 0.74 | MAP2 (0.54) | MAP2 | |
| SCHEMBL31219205 | 0.74 | MAP2 (0.66) | MAP2SIRT1KDM4EALDH1A1 | |
| SCHEMBL3253095 | 0.73 | KDM4E (0.56) | MAP2KDM4EALDH1A1HPGDTUBB4A | |
| SCHEMBL12250399 | 0.72 | MAP2 (0.54) | MAP2SIRT1KDM4EALDH1A1HPGD | |
| SCHEMBL12620039 | 0.71 | MAP2 (0.61) | MAP2SIRT1KDM4EALDH1A1 | |
| SCHEMBL12230170 | 0.70 | MAP2 (0.64) | MAP2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL2347973 | 0.70 | MAP2 (0.52) | MAP2SIRT1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078029-B1 | ENANTIOMERICALLY PURE PHOSPHOINDOLE AS HIV INHIBITOR | IDENIX PHARMACEUTICALS INC (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8486991-B2 | Enantiomerically pure phosphoindoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486991-B2 | Enantiomerically pure phosphoindoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486991-B2 | Enantiomerically pure phosphoindoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110257129-A1 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20110257129-A1 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20110257129-A1 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-7960428-B2 | (2-carbamoyl-5-chloro-1H-indol-3-yl)-[3-((E)-2-cyano-vinyl)-5-methyl-phenyl]-(S)-phosphinic acid methyl ester; Flaviviruses; bioavailability; pharmacokinetics | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960428-B2 | (2-carbamoyl-5-chloro-1H-indol-3-yl)-[3-((E)-2-cyano-vinyl)-5-methyl-phenyl]-(S)-phosphinic acid methyl ester; Flaviviruses; bioavailability; pharmacokinetics | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960428-B2 | (2-carbamoyl-5-chloro-1H-indol-3-yl)-[3-((E)-2-cyano-vinyl)-5-methyl-phenyl]-(S)-phosphinic acid methyl ester; Flaviviruses; bioavailability; pharmacokinetics | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| WO-2009124175-A1 | FORMULATIONS COMPRISING A PHOSPHOINDOLE COMPOUND AND ONE OR MORE SECOND ACTIVE AGENTS | IDENIX PHARMACEUTICALS, INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20080213217-A1 | Enantiomerically pure phosphoindoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080213217-A1 | Enantiomerically pure phosphoindoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080213217-A1 | Enantiomerically pure phosphoindoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| WO-2008042240-A9 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS INC (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008042240-A2 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257129-A1 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | DUSP3, PNP, PPP5C | MAP2 616/4885SIRT1 4458/4885KDM4E 1817/4885 |
| US-20080213217-A1 | Enantiomerically pure phosphoindoles as HIV inhibitors | DUSP3, PNP, PPP5C | MAP2 616/4885SIRT1 4458/4885KDM4E 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.